⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18807 | 0.76 | — | — | |
| SCHEMBL19985 | 0.76 | — | — | |
| SCHEMBL10707329 | 0.76 | — | — | |
| SCHEMBL23446 | 0.76 | — | — | |
| SCHEMBL2193256 | 0.71 | — | — | |
| SCHEMBL10416545 | 0.71 | — | — | |
| SCHEMBL20268130 | 0.71 | — | — | |
| SCHEMBL10852752 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL10751674 | 0.71 | — | — | |
| SCHEMBL4410824 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| CN-111757770-B | 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3737470-B1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2022-12-14 | — | — | EP | disclosed |
| CN-109476680-B | Organic magnesium phosphide, process for producing the same, complex thereof, process for producing the same, and process for producing organic phosphorus compound using the same | 北兴化学工业株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-20200399198-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2020-12-24 | — | — | US | disclosed |
| EP-3737470-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2020-11-18 | — | — | EP | disclosed |
| CN-111757770-A | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20190248815-A1 | ORGANIC MAGNESIUM PHOSPHIDE AND MANUFACTURING METHOD THEREOF, ORGANIC MAGNESIUM PHOSPHIDE COMPLEX AND MANUFACTURING METHOD THEREOF, AND MANUFACTURING METHOD OF ORGANIC PHOSPHORUS COMPOUND USING SAID PHOSPHIDE | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| WO-2019134984-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2019-07-11 | — | — | WO | disclosed |
| US-7135468-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060229310-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2006-10-12 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050234053-A1 | 9-oxo-3,4,6,9-tetrahydro-2H-[1,4]-(oxazino, thiazino, or pyrazino)[3,2-b][1,8]naphthyridine-8-carboxylic acids; fish or mammals; bacterial protein biosynthesis inhibitors | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005075477-A1 | ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050159423-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |